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Abstract
Background: Regional citrate anticoagulation (RCA) is proposed for various extracorporeal purification techniques
to overcome the risk of bleeding that might result from systemic anticoagulation. Yet, no individualized treatment
protocol has been proposed for therapeutic plasma exchange (TPE) so far. The objective of this study was to assess
the determinants of blood citrate concentration needed and to develop an individualized RCA protocol useful for
clinical practice.
Methods: The study population included 14 patients who underwent a total of 47 TPE sessions. Citrate was
infused pre-plasmafilter. Post-plasmafilter and systemic plasma ionized calcium concentrations were measured
at standardized time intervals. An algorithm was proposed for the supplementation of calcium. During the
discovery phase, citrate was infused at a fixed starting rate, and adapted accordingly to obtained post-plasmafilter
ionized calcium levels. Using a mathematical approach, an algorithm was thereafter developed for individualized
prescriptions of citrate.
Results: Pre-treatment values of hematocrit and plasma ionized calcium were the main determinants of the required
rate of citrate infusion. These can be integrated into a final equation enabling to individualize the prescription. A
prefilter ionized calcium concentration between 0.24 and 0.33 mmol/l prevented coagulation of the extracorporeal
circuit. Significant hypocalcemia occurred in 8.5% of treatments. There were no significant acid–base disturbances.
Conclusion: We propose a new protocol, which enables for the first time to individualize the prescription of regional
citrate anticoagulation during TPE, in an efficient manner. The immediately obtained regional anticoagulation protects
against both the risk of coagulation of the membrane and the exposure to an excess of citrate.
Keywords: Citrate, Clinical protocol, Drug prescription, Mathematical model, Plasma exchanges
Background
Therapeutic plasma exchange (TPE) is a method of
extracorporeal treatment that allows the subtraction and
the replacement of the plasma fraction of blood. Thus,
TPE represents a powerful tool for the rapid clearance
of various pathogenic factors, before drugs exert their
beneficial effects [1].
Anticoagulation of blood in the extracorporeal cir-
cuit (ECC) is of major importance during TPE, due
to close blood-biomaterial interaction. Systemic hep-
arin administration is the most frequently used
method but it is contra-indicated in case of high
bleeding risk. Regional anticoagulation -hence anticoa-
gulation of the ECC but not of the patient- is a valu-
able alternative in these situations [2]. Regional
anticoagulation with citrate (RCA) is achieved by pre-
filter infusion of citrate in the proximal ECC. Citrate
binds to ionized calcium in plasma, induces a local
hypocalcaemia, which prevents the activation of the
coagulation cascade. As a result of post-filter calcium
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administration and dilution, coagulation properties are
restored when the blood returns to the patient. Given
the role of ionized calcium in the activation pathways
of thrombocytes, polymorphonuclear cells and the
complement, biocompatibility may also improve dur-
ing RCA [3].
Scientific reports on the use of RCA in filtration
TPE are scarce [4], despite its rather widespread use
in clinical practice [5]. RCA is difficult to apply dur-
ing TPE for several reasons. Firstly, a given infusion
of citrate may lead to a large variability in the
plasma ionized calcium concentration of the ECC
(cCai). This often requires serial cCai measurements
in order to modify the intensity of RCA. Secondly,
the balance between the risk of ECC clotting follow-
ing insufficient citrate infusion and the risk of
citrate-related adverse events (systemic hypocalcemia,
metabolic acidosis, or alkalosis) may be difficult to
reach. This narrow therapeutic window is magnified
in TPE because of the convective nature of this
method. Indeed, no more than 30% of pre-filter
citrate is cleared through the plasmafilter, whereas in
comparison about 85% is removed by diffusion
during hemodialysis with RCA [6, 7]. Thirdly,
caution is warranted during TPE in case of the
infusion of fresh frozen plasma (FFP) as replacement
solution because FFP contains 17–21 mmol of citrate
per liter solution [8]. Most treatment protocols so
far do not follow an individualized RCA prescription.
Treatment algorithms that take into account the bio-
logical determinants of the response to citrate in
whole blood are therefore needed in order to in-
crease the security profile of RCA for TPE. In this
study we assessed the biological determinants of the
response to citrate in whole blood and developed an
individualized RCA protocol based on mathematical
models.
Methods
Patients
Regional citrate anticoagulation for TPE was the method
of reference for patients with high bleeding risk in the
Service of UNTR, Tenon hospital (APHP, Paris). Ethical
approval was not necessary for the analysis of the avail-
able data given that this was part of a quality improve-
ment and implementation approach in Tenon hospital.
Yet, patients consented orally to the plasmapheresis and
were informed of its risks and benefits and of the re-
peated measurements to be performed for safety reasons
during the procedure. No supplemental biological sam-
pling was done for the purpose of the study. Data were
analysed anonymously.
Materials and definitions
In all patients, TPEs were performed with the Multifil-
trate® monitor (Fresenius Medical Care, Germany). The
function mode “continuous veno-venous hemodialysis”
was selected to take advantage of the module “Ci-Ca”.
This module offers a dual system of enslavement for the
administration of citrate and calcium [4]. The pump
dedicated to the administration of citrate is subservient
to the blood pump while the effluent pump controls the
one dedicated to the administration of calcium. Thus,
the regional blood concentration of citrate (and thus the
intensity of the RCA) remains constant regardless of the
selected blood flow. Also, the administration of calcium
is consistently correlated to convective losses of calcium.
Additional calcium is administered through an inde-
pendent calcium pump device as needed. As another
particularity, the “dialysate” pump was used to adminis-
ter the substitution solutions (Fig. 1).
In the monitor, the flow rate of the effluent pump is
dedicated to equalize the sum of each of the following
pumps flow rates: the calcium pump, the citrate pump
and the substitution pump flow rates. Consequently, this
Fig. 1 Particularity of extracorporeal circulation (ECC) during TPE using the Ci-Ca module. I. ECC during standard regional citrate anticoagulation
(RCA) for continuous hemodialysis treatment. II. ECC during standard therapeutic plasma exchange (TPE). III. ECC during TPE with RCA using the
Ci-Ca module and the dialysate pump for plasma replacement. a Dialysate pump; b Blood pump; c Effluent pump; d replacement solution pump;
e. Kit for continuous hemodialysis treatment (I. and III.), and for TPE treatment (II.); f. Connection to venous bubble trap; g. scale for dialys-
ate solutions (I.) and for plasma replacement solutions
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system enables a neutral volume balance. Indeed, there
is compensatory excess in plasma filtration related to the
administration of the citrate and calcium solutions. This
was taken into account for the prescription of the ex-
change volume and for the choice of the replacement
solutions.
All the pumps’ flow rates were defined prior to initi-
ation of treatment and were adjusted during treatment
as needed. Blood flow rate was fixed at 180–200 mL/
min. The maximal flow rate of the substitution pump
was 40 mL/min corresponding to a filtration fraction on
plasma of 25 to 32% depending on the hematocrit (Ht)
and the predilution flow rate (Fig. 2, equation 1 and 1’).
The plasmafilter was a PF PSu 2S (polysulfone, surface
area 0.6 m2, Fresenius medical Care). Gelatin (plas-
mion®), albumin 5% and FFP were used as replacement
solutions.
ACD-A (anticoagulant dextrose-A, citrate 113 mmol/
L) was used as regional anticoagulant. ACD-A solution
was preferred to a citrate 4% solution because the citric
acid component gives 3 hydrogen ions for each citrate
molecule and therefore limits the risk of developing sig-
nificant metabolic alkalosis. Calcium was given through
a mixed calcium and magnesium chloride solution. Mag-
nesium chloride was added to compensate for the em-
pirical loss of magnesium induced by multiple successive
treatments. In the solution, the molar ratio of magne-
sium to calcium was 0.36.
Ionized plasma calcium was measured by an ion-
ometer (EH-F, Electrolyte Analyser, Fresenius Medical
Care, Germany). Hematocrit and bicarbonate were mea-
sured by the central laboratory of the hospital. Clinically
significant hypocalcemia was defined as a plasma ionized
calcium concentration (pCai) < 0.85 mmol/L with related
symptoms or signs at any time point during treatment.
Treatment failure (TF) was defined as the inability to
complete a treatment due to blood coagulation in the ECC
or as the need to restitute blood to patient because of an
ECC clotting threat as announced by a progressive eleva-
tion of TMP (trans-membrane pressure). We defined par-
tial treatment failure (PTF) as the elevation of TMP of
more than 50 mmHg, which has been correlated to a major
risk of ECC clotting in our experience with this membrane.
In PTF however, the treatment can be completed.
Study design
This study was performed in four phases:
Phase I: the goal was to determine the target range
of values for ECC ionized calcium at five minutes
treatment (cCai t5’), avoiding TF. Given the short
duration of TPE, we initially tested a low citrate
Fig. 2 Equations for the progression of the modeling
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concentration aiming a relatively high cCai t5’ of
0.35-0.40 mmol/L. This approach was chosen to
minimize the patient exposition to citrate given the
convective nature of TPE. Treatment efficacy was
characterized by the absence of TF or PTF. The target
range for cCai t5’ (corresponding to RCA intensity)
should enable treatment efficacy in more than 80% of
treatments. In order to assess the determinants of the
response to citrate, detailed information were collected.
Phase II: we tested an empirical approach of the citrate
concentration which is required in the ECC to reach
the target range of values for cCait5’, and proposed
a preliminary protocol that would allow to obtain a
maximal number of treatments with cCai t5’ in the
target therapeutic range.
Phase III: Based on data collected during the first
and second phases, a mathematical modeling approach
has been used to develop the final treatment protocol.
Phase IV: we assessed clinically the efficacy and safety
of the new treatment model.
Treatment monitoring included serial measurements
of characteristic biological parameters at key time
points (5, 30, 60, 90 min, end of treatment).
This timing was based on the pharmacokinetics
of citrate as reported in the medical literature [9].
Additional measurements were performed if deemed
necessary by the clinician. Changes in citrate infusion
rate were correlated to observed changes in cCai
and other biological variables in order to assess the
response to citrate. Treatment efficacy was again
characterized by the absence of TF or PTF.
Statistical analysis
Statistical analysis was performed using excel software
(Microsoft, Redmond, WA, USA). Quantitative values
were expressed as mean ± standard deviation or median
values (range), as appropriate. Qualitative variables were
expressed as number (percentage).
Polynomial regression analysis was used to predict
citrate-induced changes in cCai.
Results
Patients
This work included 47 TPE sessions in 14 high bleeding
risk patients; each patient received from 1 to 7 treat-
ments. Indications for TPE are shown in Table 1. RCA
was indicated because of active bleeding in eight treat-
ments (8/47, 17%). Seven treatments were performed in
three patients after renal transplantation.
Treatment characteristics
Blood flow was 200 mL/min, corresponding to a mean
plasma flow of 153 mL/min. Substitution rate was 2.4 L/
h. Mean total treatment time was 106.9 (±25.1 SD)
minutes. Mean exchange volume per treatment was 4.20
(±0.72 SD) liters corresponding to 62.4 mL/kg/body
weight. The high prevalence of anemia accounts for this
relatively high volume exchange. Haven taken into ac-
count the predilution volume (which is compensated by
plasmafiltration), mean total exchange volume was 4.96
(±0.88 SD) liters. However, this supplemental exchange
volume is somewhat mitigated by the dilution process.
Most treatments (35/38, 92%) included FFP, in 11/14 pa-
tients. This was due the high prevalence of thrombotic
microangiopathy in the study population and because
most of the patients were either bleeding or at high risk
of bleeding. FFP constituted more than 80% of total sub-
stitution volume during TPE for thrombotic microangi-
opathy. In other conditions, FFP constituted between
20% (high bleeding risk) and 60% (ongoing bleeding) of
total prescribed substitution volume. In 38 TPE, 17
(44.7%) included albumin 5% and 14 (36.8%) included
both FFP and albumin 5%. A gelatin solution (Plasmion®)
constituted nearly all the non-albumin and non-FFP
fraction. Use of sodium chloride was marginal.
Altogether, albumin-rich replacement solutions (albumin
and FFP) constituted 83.2% of total prescribed substitu-
tion volume. When considering the added predilution
solutions (ie ACD-A, calcium), the albumin-rich replace-
ment solutions constituted 72.8% of total exchanged
volume.
Phase I: determination of the target range values for
cCai t5’, avoiding TF.
A standardized prescription of citrate and calcium was
tested in the first five TPEs performed in three patients,
Citrate was perfused pre-filter at a concentration of 2.4
– 3.0 mmol/L of whole blood, aiming a target cCai of
Table 1 Demographic and clinical characteristics of the study
patients and treatments
Characteristics of the patients
Number of patients 14
Sex, n, Female/Male 5/9
Age, years (mean ± standard deviation) 52.6 ± 17.83
Treatment characteristics
Median number of treatments per patient 2.5
TPE indication (N = 47), n (%)
Thrombotic microangiopathy 25 (53)
Acute humoral rejection 8 (17)
ANCA-associated vasculitis 7 (15)
Antiglomerular basal membrane vasculitis 3 (6)
Cryoglobulinemia associated vasculitis 2 (4)
Neurological diseases 2 (4)
TPE during active bleeding, n (%) 8 (17)
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0.35-0.40 mmol/L which correspond to a relatively low
concentration as mentioned earlier.
This infusion rate led to the predefined cCai target, but
was associated with TMP elevation and TF (Table 2).
For the next treatments, we therefore lowered the cCai
target range to 0.25-0.35 mmol/L, which corresponds
to the target mostly reported in the literature in various
modalities of RRT [6, 10, 11]. This range, deemed
appropriate, has been tested in the next successive
treatments.
Phase II: Empirical approach of the citrate
concentration needed in the ECC
For the next treatments, we empirically increased
WBCi to 3.6 mmol/L in order to reach the new target
range for cCai t5’ (ie 0.25-0.35 mmol/L). Based on
physiological considerations and an analysis of the first
treatments parameters, pre-treatment pCai and the
Ht were strongly associated with the efficacy of a given
dose of citrate. Indeed, since citrate is prescribed in
whole blood according to the blood pump and does
not enter the erythrocyte, its plasma concentration
is assumed to depend on the patient's Ht (Fig. 2,
equation 2).
Concerning pCai, we observed that the citrate
concentration required in plasma to lower ionized
calcium concentration by one millimole per liter
(equivalent to the ratio pCi/pCait0’), was about 4.6
millimoles. Based on the assumption that this value
is constant, we developed a first prescription protocol
for RCA, which integrated cCait0’ and Ht (Fig. 2,
equation 3 and 3’).
The objective of this preliminary protocol was to
obtain a large number of treatments in the target
therapeutic range for cCai t5’, that would allow later
the development of a mathematical modeling.
Thus, this preliminary protocol or, alternatively a fixed
citrate dosing (WBCi) of 3.6 mmol/L was applied in
the next 42 following treatments beyond the first step.
Among these, 38 were sufficiently well documented
for the plasma values of both pre-treatment ionized cal-
cium and circuit ionized calcium. These 38 TPE could
be therefore included in the next phase (modeling
process).
In these 38 TPE, no TF was observed. Aside from
two cases (2/38, 5.3%) of PTF that occurred in
relation with technical problems (catheter dysfunction,
interruption of RCA), any rise of the TMP (4/38,
10.5%) was systematically associated with at least one
measurement of cCai above or equal to 0.35 mmol/L
at any time during the treatment. Therefore, we
adjusted the target range of values for cCait5’ from
0.25-0.35 to 0.24-0.33 mmol/L.
Phase III: Modeling approach
When circuit plasma ionized calcium concentration is
within the target range (0.24-0.33 mmol/L, in 30 out
of 38 treatments), the ratio pCi/pCait0’ expresses the
amount of citrate (in mmol) in one liter of plasma
that is required to neutralize one millimole of calcium.
As mentioned previously, we assumed that pCi/pCait0’
was constant (4.6 mmol/mmol) and thus may be used
for the calculation of whole blood citrate dosage in any
individual patient, knowing pre-treatment pCait0’ and
Ht (Fig. 2, equation 3’).
We further analysed pCi/pCait0’ and the ratio pCi/
DeltaCai, where DeltaCai is the difference between
pCait0’ and cCai t5’. DeltaCai also represents the
amount of calcium becoming chelated by citrate in
1 l of plasma.
For relatively higher pre-treatment pCai, we found
that the ratio pCi/DeltaCai is lower (Fig. 3a, b, c).
Indeed, less citrate in regard to calcium is needed to
reach the therapeutic target. This may be explained
by a larger availability of plasma calcium for citrate
in case of high plasma calcium concentration.
Accordingly, pre-treatment hypocalcemia was
associated with a relative resistance to citrate
treatment.
Using a polynomial regression model, we showed a
highly significant correlation between the ratio
pCi/deltaCai(t0’-5’) and pCait0’, in a given individual
and for all the treatments taken together (correlation
coefficient R2 = 0,723, Fig. 3b and c). A similar
correlation was noted between massic flow rates of
both citrate and calcium (Fig. 3a). This correlation
allowed to progress in the development of a
prescription protocol (equation 4, Fig. 2).
In order to obtain an expression of the citrate
concentration pCi (corresponding to the prescription
of citrate in plasma) from pCait0’, we introduced
empirically in equation 4 (Fig. 2) a value for cCai t5’
in the middle of the target range, ie 0.285 mmol/L
(equation 5, Fig. 2, Fig. 4).
Equation 5’, illustrated in Fig. 2, integrates the Ht and
may be used for the determination of the initial dose of
citrate in whole blood.
Table 2 First 5 TPE aiming a cCait5’ of 0.35-0.40 mmol/L
N° Pt. Ttt Ht (%) pCai t0’ CiWB cCai t5’ cCai max PTF TF
A.1 40 1.14 2.4 0.40 0.42 Y N
B.1 27 1.00 2.4 0.37 0.37 Y Y
B.2 25 1.07 2.4 0.41 0.41 Y N
B.3 26 0.83 2.4 0.40 0.47 Y Y
C.1 27 1.27 3.0 0.39 0.39 y Y
N° pt.Ttt, Patient.Treatment Number; Ht (%), Hematocrit; pCai, patient ionized
plasma calcium [mmol/L]; cCai, circuit plasma ionized calcium [mmol/L]; t0’,t5’,
0, 5 min treatment, respectively; max, maximal value during treatment; CiWB,
whole blood citrate concentration [mmol/L]; pCi, plasma citrate concentration
[mmol/L]; PTF, partial treatment failure; TF, treatment failure
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Phase IV: Clinical safety and efficacy analysis
The retrospective application of this new formula
to the values of pre-treatment pCai of the 47
treatments of the study, allowed to improve both
citrate underdosing (cCai at t5' > 0.33 mmol/L in 4
treatments) and overdosing (cCai at t5' <0.24 mmol/L
in 4 treatments). This was at the price of a slight rise
in citrate dosing in 6 treatments during which dosing
was already adequate.
Concerning safety, we managed to adapt calcium
infusion according to a pre-defined protocol.
A cautious clinical monitoring and the timing of
the serial measurements of pCai allowed for the
identification of biological anomalies which were
corrected with the application of a systematic
algorithm (Additional file 1: Table S1 and
Additional file 2: Table S2). Clinically significant
hypocalcemia was observed in four (8.5%) treatments
and were corrected with calcium chloride administration
without complication. Total calcium rose signifi-
cantly during treatment as a consequence of calcium
administration to maintain pCai balance (Fig. 5).
This was associated with a concurrent elevation of
the ratio pCa total/pCai (Table 3). As expected,
the highest values of the pCa total/pCai ratio were
observed during TPE with large amount of FFP
as the substitution solution. Unexpectedly however,
there were no proportional differences in the amount
of the calcium infused nor in the concentration of
post-treatment pCai (Fig. 6).
We did not observe any new episode of bleeding,
worsening of a pre-existing bleeding, nor clinically
significant electrolytes and acid–base disturbances
(Additional file 3). We considered as a clinically significant
acid–base disturbance any metabolic alcalosis or acidosis
that was complicated by an adverse clinical event
requiring a medical intervention. Mean bicarbonate
elevation per treatment appeared to be proportional
Fig. 4 Theoretical plasma citrate concentration (pCi) that is needed
to obtain therapeutic postfilter anticoagulation (cCait5’, 0.285 mmol/L)
and its relation to patient pre-treatment plasma ionized calcium
concentration (Cait0’). Third degree polynomial equation derived
from the polynomial second degree expression of the
ratio Cip/DeltaCai
Fig. 3 a QmCi/DeltaCai’ as a function of QmpCait0’. Relation
(pre-plasmafilter, t5’) between the ratio « QmCi/DeltaCai’ »
(patient massic flow rate of citrate correlated to the induced variation
of the massic flow rate of plasma ionized calcium) and « QmpCait0’ »
(t0’ massic flow rate of ionized plasma calcium, based on pre-treatment
plasma concentration of ionized calcium). b pCi/DeltaCai as a function
of pre-treatment pCai (pCait0’). Relation (pre-plasmafilter, t5’) between
the ratio « pCi/DeltaCai » (patient plasma ionized calcium concentration
correlated to the induced variation (t0’-t5’) of plasma ionized calcium
concentration) and pCait0’ (pre-treatment patient plasma ionized
calcium concentration). c pCi/DeltaCai as a function of pre-treatment pCai
(pCait0’ [mmol/L]). Same relation as in b) per patient in 7 patients
Fig. 5 Plasma concentrations of ionized (pCai) and total (total pCa)
during treatment. Time 0,30,60,120 min and Z (end) of treatment
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to FFP volume, as was pH elevation (Fig. 7). In four
patients undergoing 5 to 6 daily consecutive TPE
using FFP for more than 80% of total replacement
solutions (mean total FFP = 21 L ± 3.71 SD), mean
bicarbonate variation throughout the period of treatment
was significant (+14.5 mmol/L ± 8.76 SD, from an
initial mean bicarbonate concentration of 20 ± 4.32
SD mmol/L). However, mean pH variation was relatively
modest (+0.1 ± SD 0.06 units). None of them required
medical intervention.
Discussion
Taken together, this report describes a new, individual-
ized prescription protocol for RCA based on the pre-
treatment pCai and Ht. The pivot of the work is to dem-
onstrate how to develop a mathematical model built to
improve and individualize the prescription of citrate in-
fusion, namely the concentration of citrate in whole
blood that is actually required to optimize the treatment.
We first defined the most adequate concentration
of calcium in the circuit which should be between 0.24
and 0.33 mmol/l. Our data show that there is a close
correlation between the needed citrate concentration in
whole blood and pre-treatment values of pCai and
hematocrit. Thus, the application of this model should en-
able to propose a more individualized prescription of RCA
in TPE.
Regional citrate anticoagulation is particularly difficult
to apply in patients undergoing TPE because of the nar-
row therapeutic window and the risk of citrate overdos-
ing. This is probably the main reason why this method is
not commonly used in clinical practice. Indeed, there is
no literature on the habits relative to the use of RCA for
TPE in apheresis centers worldwide. Another reason for
its limited use might be the labor intensity associated
with RCA.
As mentioned previously, we have evaluated whether a
relatively high calcium concentration in the ECC would
allow treatment efficacy. Our experiments stress that cCai
values should be lower than 0.33 mmol/L to insure efficacy.
This is in accordance with the fact that a very close
blood-biomaterial interaction precludes any compromise
on the intensity of anticoagulation during TPE. Accordingly,
achieving immediately effective anticoagulation should
protect against the risk of clotting of the system.
Our study strongly also suggests that a fixed univer-
sal prescription of citrate in whole blood is not ap-
propriate since it could lead to a higher number of
ECC clottings. According to our model, this would be
especially the case in anaemic and hypercalcemic pa-
tients. In this work, we illustrate that pre-treatment
Ht and circuit ionized calcium concentration (cCai)
are the strongest predictors of the amount of needed
citrate. This is not surprising given the fact that cit-
rate does not enter the erythrocyte and that pCai is
chelated by citrate.
Regarding the efficacy, our data suggest that the
model should enable a better prediction of the amount
of needed citrate, thanks to the individualization of
Fig. 6 Relation between Fresh Frozen Plasma (FFP) volume and the ratio pCa total/pCai, post-treatment pCai and total amount of calcium infused
during RCA TPE
Table 3 Pre-treatment and post-treatment plasma values of
pCai, pCa total, the ratio pCa total/pCai, pH and bicarbonates
(mean ± SD))
Pre-treatment (t0’) Post-treatment
pCai (mmol/l) 1.00 ± 0.1 1.02 ± 0.07
pCa total (mmol/l) 2.04 ± 0.14 2.58 ± 0.25
pCa total/pCai - 2.53 ± 0.28
pH 7.47 ± 0.05 7.48 ± 0.04
Bicarbonate (mmol/l) 26.4 ± 4.9 27.6 ± 5.5
pCai, patient ionized plasma calcium; pCa total, patient plasma total calcium
Kissling et al. BMC Nephrology  (2017) 18:81 Page 7 of 10
the prescription. Yet, this needs validation in pro-
spective studies.
As such, the application of this protocol should limit
both the risk of citrate overdosing and the risk of clot-
ting of the ECC. Furthermore, and of most importance
during TPE, the application of this model is likely to
reduce the time to reach target cCai. So, this protocol
has the potential to reduce the labor-intensity of
RCA-based TPE.
The patients we treated showed a high incidence of
citrate accumulation as defined by a pCa total/pCai
ratio > 2.5 [12]. Obviously, hypocalcemia that results
from citrate accumulation, rather than the citrate plasma
concentration by itself, is the causative factor of citrate
toxicity. We think therefore that citrate accumulation
should not be used as a surrogate for citrate intoxication
without looking closely at pCai and plasma bicarbonate
concentrations. Furthermore, we should underscore that
the pCa total/pCai ratio is an “a posteriori” indicator of
citrate accumulation that cannot be used to monitor the
treatment in real time during TPE as it is during a slow
continuous blood purification method. Moreover during
filtration TPE, citrate accumulation is due mostly to a
high citrate flow rate to the patient rather that to a
defective metabolism. This is further supported by a
post-treatment rise in plasma bicarbonate concentra-
tion mostly in case of a high amount of substitution
by FFP (Fig. 7).
Although we observed a relatively high rate of ionized
hypocalcemia in this study, this cannot be attributed to
the RCA prescription model by itself. We believe that
this was merely due to the high blood flow (ie 200 mL/
min), which exposes the patient to a high citrate load.
This hypothesis is supported by Fig. 6, which suggests
that the dependence of citrate accumulation (i.e. pCa
total/pCai > 2.5) on the volume of FFP is not associated
with a simultaneous proportional excess in the incidence
of post-treatment hypocalcemia nor a larger amount of
calcium infusion. The calcium content of donor FFP
most probably gives a part of the explanation for this in-
teresting observation.
In the future, a reduction of the blood flow should
lessen the citrate load without changing the validity of
the protocol. The substitution solution also plays an im-
portant role in the incidence of hypocalcemia. When
FFP are administered as a substitute, the infusion of the
minimal effective dose of citrate is crucial. Indeed, FFP
contains large amounts of citrate with no anticoagulant
value. Therefore, in order to limit the patient exposition
to citrate, the flow of the blood pump should be lowered
to 120–150 mL/min during plasma substitution with
FFP. At the same time, the rate of replacement should
not exceed 1600 mL/h. Given the small number of treat-
ments (only four with PTF), we were not able to demon-
strate any difference in the incidence of PTF between
treatment with and without FFP. However, PTF seemed
not to be associated with the use of FFP (no PTF ob-
served) nor with the duration of treatment (106.25 min
for the 4 TPE showing PTF vs 106.9 min).
Whatever the modality of treatment prescription and
monitoring, application of RCA for TPE requires a great
expertise of both the medical and the nurse team. In
particular, excellent knowledge is necessary in the
fields of electrolytes disorders and citrate metabolism.
Furthermore, everyone who prescribes or manages
such treatment must thoroughly know how to handle
the functionality of the monitor and how to react in
case of alarms.
This study must be seen in the light of its strengths
and limitations. Among its strengths are the use of
the same experienced treatment team throughout the
study, and the use of a discovery and a development
phase with a mathematical approach. Among its limi-
tations are the relatively limited number of TPE per-
formed in this work and the heterogeneity of the
treatment indications. Besides, only few treatments
Fig. 7 Mean values (and standard deviation, SD) for treatment-induced variation in (a) plasma bicarbonate concentration (delta-HCO3), and
(b) plasma pH (delta-pH). From 38 therapeutic plasma exchanges. Delta-HCO3 appeared proportional to the volume of FFP infused as a
replacement solution
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were available within the highest ranges of calcium
levels. Therefore, there might have been some degree
of bias when this protocol was applied in the upper
fields of pre-treatment pCai values.
Finally, a local validation of the curve expressing the
pCi needed in the ECC as a function of pCait0’ is an ab-
solute prerequisite before starting using this prescription
protocol. Most ionometers are indeed not validated to
measure cCai in the range of values required for RCA.
In our experience, we observed that the application of
this protocol with some others ionometers could lead to
a systematic under dosing of the pCi. This argues for the
need to calibrate individually the prescription formula
with the local ionometer. However, these limitations
should not prevent the application of this protocol at a
large scale.
Conclusions
We propose a new model, which enables for the first
time to individualize the prescription of RCA during
TPE. Application of this new model should result in an
improvement of the quality of the treatment by limiting
both the risk of citrate overdosing and the risk of clot-
ting of the ECC. This hypothesis needs to be validated in
a prospective study.
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Additional file 1: Table S1. Table for the adaptation of calcium
infusion depending on pCai t30’ and following controls. Remark:
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hospital to another, based on local parameters (ionometer, TPE device,
applied blood flow). (TIF 113 kb)
Additional file 2: Table S2. Table for the prescription of the initial rate
of calcium infusion (dependence on the effluent flow). (TIF 21 kb)
Additional file 3: Figure S1. Post-treatment variation in plasma
magnesium (Mg) concentration (x-axis) according to pre-treatment
concentration (y-axis). (TIF 87 kb)
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